Premium
A novel mutation in the DYSF gene in a patient with a presumed inflammatory myopathy
Author(s) -
Tang Jin,
Song Xueqin,
Ji Guang,
Wu Hongran,
Sun Shuyan,
Lu Shan,
Li Yuan,
Zhang Chi,
Zhang Huiqing
Publication year - 2018
Publication title -
neuropathology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.701
H-Index - 61
eISSN - 1440-1789
pISSN - 0919-6544
DOI - 10.1111/neup.12474
Subject(s) - dysferlin , missense mutation , sanger sequencing , muscular dystrophy , mutation , muscle biopsy , myopathy , genetics , medicine , gene mutation , gene , pathology , bioinformatics , biology , biopsy
Dysferlinopathy, a progressive muscular dystrophy, results from mutations in the Dysferlin gene ( DYSF , MIM*603009). Traditional diagnosis relies on the reduction or absence of dysferlin. However, altered dysferlin has been observed in other myopathies, leading to a precise diagnosis through molecular genetics. In this study, we report a patient who was previously misdiagnosed as inflammatory myopathy based on routine clinicopathological examinations alone. However, muscle biopsy specimens were analyzed further by immunohistochemistry of muscular dystrophy‐related proteins, and gene‐targeted next generation sequencing (NGS) was used to correctly identify muscular dystrophy. DNA was sequenced with NGS and the detected mutation was verified by Sanger sequencing. Our targeted NGS found a novel missense mutation (c.5392G > A) in the DYSF gene, allowing correct diagnosis of LGMD2B in our patient. We discovered of a novel missense mutation in the DYSF gene and have broadened the DYSF mutation spectrum, which may be correlated in patients with presumed dysferlinopathy, especially when lymphocytic infiltration is observed.